The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians ...
Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 ...
We apologize, but this video has failed to load. The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron, the agency said. It replaces the previous ...
Specifically, in 2021-2023, Moderna invested proceeds from its pandemic-era vaccine sales into building a diverse pipeline and established the market for its COVID-19 vaccine, Spikevax®. In 2023-2026, ...
The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at least 25 U.S. states, according to reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback